• br It is reasonable to postulate that cancer

  2022-09-17

  

  It is reasonable to postulate that cancer patients, particularly those free of advanced disease, should share similar resuscitation rates compared to cancer-free patients. Yet, whether cancer patients share similar improvements in post-IHCA outcomes and post-arrest cardio-resuscitory procedural ut

• br Discussion br In this study we demonstrate

  2022-09-17

  

  4. Discussion In this study, we demonstrate that genomic alterations of TP53, PTEN, or RB1 are common events across the entire clinical spectrum of significant prostate cancer. Leveraging the application of a clinical-grade targeted sequencing assay (OncoPanel) and using clinical FFPE tumor spe

• br Fuquan Zhang and Ke

  2022-09-17

  

  1 Fuquan Zhang and Ke Hu contributed equally to this work. Introduction Cervical cancer is one of the most common cancers in China. In 2015, it K 252a was estimated that there were 98.9 thousand new cases and 30.5 thousand deaths from cervical cancer [1]. With the use of the human papillomav

• br Characterization of micelles br Micelles were successfully prepared

  2022-09-16

  

  3.2. Characterization of micelles Micelles were successfully prepared with Soluplus® and TPGS, as shown in Table S1. The ratio of Soluplus® to TPGS (4:1) was optimized via preliminary tests (data not shown). We selected methylene chloride as the organic solvent, which could easily be removed, a

• br Methods This population based cohort study used

  2022-09-16

  

  Methods: This population-based cohort study used Surveillance, Epidemiology, and End Results − Medicare data. Eligible patients were men aged 66 or older and diagnosed with high-risk prostate cancer between 1996 and 2003. Outcomes evaluated were 10-year overall mortality and prostate cancer-specif

• br Conclusion A urinary integrated panel

  2022-09-15

  

  Conclusion: A urinary integrated panel of methylation and miRNA markers is a promising approach to identify AS patients at risk for reclassification. Our 3-marker panel, with its high negative predictive value, would be beneficial to identify and preclude AS patients with truly indolent cancer and

• CP-456773 br this is standard clinical practice In the case

  2022-09-15

  

   this is standard clinical practice. In the case of CBCT-US registration (henceforth referred to as CBCT-US fusion), the planning CT was available for reference in a separate window rather than as a third superimposed image. Image contouring and rating Observers used the MATLAB application

• C11 BODIPY 581/591 br Results br The bPFS local recurrence free survival

  2022-09-15

  

  Results The bPFS, local recurrence-free survival, and metastases-free survival (MFS) at 5 years were 87.1%, 95.5%, and 96.3%, respectively. The prostate cancer-specific survival and OS at 5 years were 100% and 92%, respectively. As shown in Table 2, we were unable to establish any predictors of

• br Results A total of patients

  2022-09-15

  

  Results: A total of 24 (7.5%) patients (male, n ¼ 21; female, n ¼ 3; median age, 67 years; performance status, 0–1/Z2, 15/8 patients; limited/extensive disease, 6/15 patients; sensitive/refractory relapse, 3/21 patients) were treated with carboplatin plus paclitaxel. This regimen was chosen due to

• br Fig CT imaging properties of CUSCs PEG FA a

  2022-09-15

  

  Fig. 7. CT imaging properties of CUSCs-PEG-FA. (a) In vitro CT images of CUSCs-PEG-FA with different Gd and Yb concentrations. (b) CT values of CUSCs-PEG-FA aqueous solutions as a function of the Gd and Yb concentrations. (c) CT images of tumor-bearing Balb/c mouse before (up) and after (below) inj

• br Results br Table presents

  2022-09-14

  

  Results Table 1 presents a sociodemographic and clinical description of both patient groups. Regarding sex, education, and place of residence, patients did not differ significantly between groups (inpatient unit vs home). In the area of age, a tendency towards higher values in the home-care

• br Cytocompatibility evaluation br The Cell Counting Kit CCK

  2022-09-14

  

  2.10. Cytocompatibility evaluation The Cell Counting Kit-8 (CCK-8, KGA317, KeyGEN BioTECH, Nanjing, China) assay was conducted to quantitatively indicate the activity of 3T3 or 4T1 BODIPY 493/503 cultured with different samples. The cells were dissociated with Trypsin-EDTA Solution firstly and

• matched pairs analysis using McNemar test was

  2022-09-14

  

  matched-pairs analysis using McNemar test was carried out to test stroma expression differences. Pb.05 was considered statistically significant. Analyses were carried out using SPSS v24 (IBM, New York, NY) and SAS, v9.2 (SAS Institute, Cary, NC). 3. Results 3.1. DepArray analysis reveals a sma

• br FISH assay was performed using

  2022-09-13

  

  FISH assay was performed using the Zytolight SPEC ROS1 Dual Color Break Apart Probe (ZytoVision, Germany). This break-apart FISH test is based on a mixture of two probes hybridizing to the proximal (3’, green-labeled probe) and distal (5’, orange-labeled probe) to the ROS1 breakpoint cluster regio

• br CEA is a nonspecific

  2022-09-08

  

  CEA is a nonspecific biomarker with abnormal KRN 7000 in several solid tumors including gastric cancer. Contradictory results concerning the prognostic effect of pretreatment CEA level have been reported.50-52 In our results, patients with high pretreatment serum CEA level were associated with sh

180 records 1/12 page Next 12345 Next 5 pages Last page